Inventor · disambiguated record
Yu Kyeong Hwang
Also filed as: HWANG YU HA · HWANG YU KYEONG
8 granted patents·21 pending applications·31 citations·filing 1998–2024
81Inventor score
Files withGC CELL CORP10ARTIVA BIOTHERAPEUTICS INC8GREEN CROSS LAB CELL CORP5MOGAM BIOTECH RES INST3MOGAM BIOTECHNOLOGY INST1
Top patents by PatentIndex Score
29 records- 0187US7785875B2Polynucleotide encoding HCV epitopes which can bind to various HLA supertypes, immunogenic composition comprising same and method of inducing an HCV-specific immune response using sameMOGAM BIOTECH RES INST·Filed 2008·Granted Aug 31, 2010·11 cites·15 claims
- 0286US11766456B2Method for culturing natural killer cells using T cellsGC CELL CORP·Filed 2021·Granted Sep 26, 2023·2 cites·14 claims
- 0382US9834753B2Method for producing natural killer cells, natural killer cells produced thereby, and composition for treating cancers and infectious diseases containing the sameMOGAM BIOTECHNOLOGY INST·Filed 2012·Granted Dec 5, 2017·16 cites·9 claims
- 0471US2025109380A1Method for culturing natural killer cell, using transformed t cellGC CELL CORP·Filed 2024·Application pending·0 cites
- 0571US2024050478A1Method for Culturing Natural Killer Cells Using T CellsGC CELL CORP·Filed 2023·Application pending·0 cites
- 0667US12435118B2Chimeric antigen receptor and natural killer cells expressing sameGC CELL CORP·Filed 2022·Granted Oct 7, 2025·0 cites·5 claims
- 0765US2023108578A1Medium Composition for Cryopreservation of Cell and Use ThereofGC CELL CORP·Filed 2022·Application pending·0 cites
- 0862US2025243461A1Method for introducing target gene into immune cellsGC CELL CORP·Filed 2023·Application pending·0 cites
- 0960US12203065B2Method for culturing natural killer cell, using transformed T cellGC CELL CORP·Filed 2018·Granted Jan 21, 2025·0 cites·30 claims
- 1058US2025282845A1Fusion proteins comprising chimeric antigen receptors and il-15GC CELL CORP·Filed 2022·Application pending·0 cites
- 1153US2023242894A1Novel transplantation cells having reduced immunogenicityGC CELL CORP·Filed 2021·Application pending·0 cites
- 1253US2025073264A1Chimeric antigen receptor comprising an anti-her2 antibody or antigen-binding fragment thereof and natural killer cells comprising the sameARTIVA BIOTHERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1352US2024180962A1Treatment of cancer with nk cells and a cd20 targeted antibodyARTIVA BIOTHERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1451US12491244B2Pharmaceutical combinations for treating tumor comprising anti-CD19 antibody and natural killer cellGC CELL CORP·Filed 2019·Granted Dec 9, 2025·0 cites·23 claims
- 1550US2024366663A1Chimeric antigen receptor comprising an anti-cd19 antibody or antigen-binding fragment thereof and natural killer cells comprising the sameARTIVA BIOTHERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1648US2024366664A1Treatment of cancer with nk cells and an egfr targeted antibodyARTIVA BIOTHERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1748US2024197778A1Treatment of cancer with nk cells and a her2 targeted antibodyARTIVA BIOTHERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1847US2024115704A1Treatment of cancer with nk cells and a cd38-targeted antibodyARTIVA BIOTHERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1947US2024000840A1Treatment of cancer with nk cells and a cd20 targeted antibodyARTIVA BIOTHERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2047US2024060046A1Expanded and stimulated natural killer cellsARTIVA BIOTHERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2145US2019037831A1Medium composition for cryopreservation of cell and use thereofGREEN CROSS LAB CELL CORP·Filed 2017·Application pending·0 cites
- 2243US12398372B2Method for culturing cord blood-derived natural killer cells using transformed T-cellsGREEN CROSS LAB CELL CORP·Filed 2019·Granted Aug 26, 2025·0 cites·11 claims
- 2342US2017319621A1Method for culturing natural killer cells using t cellsGREEN CROSS LAB CELL CORP·Filed 2015·Application pending·0 cites
- 2441US2021147803A1Method for producing natural killer cellsGREEN CROSS LAB CELL CORP·Filed 2019·Application pending·0 cites
- 2541US2002151683A1Liposomes comprising peptide antigens derived from X protein of hepatitis B virusMOGAM BIOTECH RES INST·Filed 2001·Application pending·0 cites
- 2639US2019336533A1Chimeric antigen receptor and natural killer cells expressing sameGREEN CROSS LAB CELL CORP·Filed 2017·Application pending·0 cites
- 2737US2004146968A1Three dimensional structure of human derived apoptotic factor and receptor thereof x-ray crystallography and trail deletion mutant proteinFiled 2001·Application pending·0 cites
- 2835US2008112977A1Supertype Epitopes, Oligonucleotides Coding The Same Which Induce Effective Ctl Response Against Hcv And The Use ThereofMOGAM BIOTECHNOLOGY RES·Filed 2005·Application pending·0 cites
- 2930US6380359B1Liposomes comprising peptide antigens derived from X protein of hepatitis B virusMOGAM BIOTECH RES INST·Filed 1998·Granted Apr 30, 2002·2 cites·2 claims
Join the waitlist — get patent alerts
Get an alert when Yu Kyeong Hwang files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →